Pharmaceuticals Analysts discuss key takeaways from Sanofi’s (SNY) investigational therapy, Alphamedix, on an Analyst/Industry conference call to be held on November 24.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Advances with Dupixent and Teizeild Approvals in November 2025
- Sanofi facility in France cited for quality control issues by ANSM
- FDA appoints Richard Pazdur as Director of CDER
- Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study